SCHEMBL23055231

SCHEMBL23055231

CC(C)(C)OC(=O)Cn1ncc2ccc(Cl)nc21

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
KMO O15229 5/20 0.37
NPC1 O15118 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MITF O75030 1/20 0.37
HTT P42858 1/20 0.37
CCR9 P51686 1/20 0.36
KMT2A Q03164 3/20 0.35
LMNA P02545 1/20 0.35
MEN1 O00255 1/20 0.34
RAB9A P51151 1/20 0.34
WNT1 P04628 1/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
FPR2 P25090 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23055222 0.82 STK17B (0.39) ALDH1A1KDM4EKMONPC1SMN1; SMN2
SCHEMBL23055344 0.81 KDM4E (0.43) ALDH1A1KDM4E
SCHEMBL15157126 0.80 KDM4E (0.44) ALDH1A1KDM4ENPC1SMN1; SMN2KMT2A
SCHEMBL23639069 0.79 KMO (0.57) ALDH1A1KDM4EKMONPC1SMN1; SMN2
SCHEMBL32674371 0.78 PDE4D (0.37) ALDH1A1KDM4ENPC1SMN1; SMN2MITF
SCHEMBL16293127 0.77 HDAC6 (0.40) ALDH1A1KDM4ECCR9KMT2ALMNA
SCHEMBL23055250 0.76 GPR119 (0.38) ALDH1A1NPC1SMN1; SMN2LMNARAB9A
SCHEMBL24783896 0.74 ALDH1A1 (0.37) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL31469700 0.74 HTR2A (0.34) ALDH1A1KMONPC1SMN1; SMN2MITF
SCHEMBL24779604 0.74 ALDH1A1 (0.68) ALDH1A1NPC1SMN1; SMN2MITFHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed
EP-4104861-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2022-12-21 EP disclosed
WO-2021141041-A1 THERAPEUTIC AGENT FOR TAUOPATHIES 大日本住友製薬株式会社 2021-07-15 WO disclosed
WO-2021039961-A1 RING-FUSED PYRAZOLE DERIVATIVE 大日本住友製薬株式会社 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 ALDH1A1 4081/4885KDM4E 3621/4885KMO 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.